Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of maternal RSV prefusion F subunit vaccine to protect infants
2019-002943-85Phase 3Completed
- Sponsor
- Pfizer
- Start
- Mar 2020
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in respiratory syncytial virus disease (RSV) and respiratory syncytial virus lower respiratory tract infection comparing PF-06928316 RSV prefusion F vaccine with Placebo (2 arms). Primary endpoints: Primary Efficacy Objectives – Infant Participants and Primary Safety Endpoints – Maternal Participants. Started Mar 2020; status: completed.
02
Drugs
RSVpreF vaccine
03
Conditions
respiratory syncytial virus disease (RSV)respiratory syncytial virus lower respiratory tract infection
Beyond the preview
Go deeper on 2019-002943-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002943-85.